Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 15/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886558 | 0.94 | CAPN1 (0.44) | BTKCAPN1TACR3 | |
| SCHEMBL22886377 | 0.90 | CAPN1 (0.45) | BTKCAPN1 | |
| SCHEMBL22885866 | 0.90 | ACE (0.40) | CAPN1TACR3GAA | |
| SCHEMBL22886527 | 0.89 | CAPN1 (0.46) | CAPN1 | |
| SCHEMBL22886870 | 0.89 | CAPN1 (0.38) | CAPN1GAA | |
| SCHEMBL20027721 | 0.88 | CAPN1 (0.55) | CAPN1 | |
| SCHEMBL30133598 | 0.88 | CAPN1 (0.55) | CAPN1 | |
| SCHEMBL22886878 | 0.86 | CAPN1 (0.42) | CAPN1 | |
| SCHEMBL22886415 | 0.86 | DCAF1 (0.52) | CAPN1TACR3 | |
| SCHEMBL22886516 | 0.84 | CAPN1 (0.47) | BTKCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| CN-112703188-A | Method for treating liver fibrosis using calpain inhibitor | 布莱德治疗公司 | 2021-04-23 | — | — | CN | disclosed |
| US-20210113560-A1 | METHOD OF TREATING FIBROTIC DISEASE | BLADE THERAPEUTICS INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
| CN-112204014-A | Calpain modulators and therapeutic uses thereof | 布莱德治疗公司 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | BTK 4610/4885CAPN1 4/4885TACR3 3285/4885 |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | BTK 4489/4885CAPN1 3/4885TACR3 4071/4885 |
| US-20210113560-A1 | METHOD OF TREATING FIBROTIC DISEASE | CAPN9, CAPNS1, CAPN1 | BTK 4475/4885CAPN1 3/4885TACR3 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.